A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre) in the Treatment of Mild-to-high Hypertriglyceridemia.

Trial Profile

A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre) in the Treatment of Mild-to-high Hypertriglyceridemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2014

At a glance

  • Drugs NKPL 66 (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Acronyms TRIFECTA
  • Sponsors Acasti Pharma
  • Most Recent Events

    • 21 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Oct 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 04 Dec 2012 Planned end date changed from 1 Nov 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top